Resource Logo
AIDS Weekly Plus

Reports from University of Pittsburgh School of Medicine Advance Knowledge in HIV/AIDS




 



2013 OCT 7 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- Fresh data on Immune System Diseases and Conditions are presented in a new report. According to news reporting out of Pittsburgh, Pennsylvania, by NewsRx editors, the research stated, "Individuals practicing unprotected receptive anal intercourse are at particularly high risk of HIV infection. Men who have sex with men (MSM) in the developed and developing world continue to have disproportionate and increasing levels of HIV infection."

Our news journalists obtained a quote from the research from the University of Pittsburgh School of Medicine, "The past few years have seen important progress in demonstrating the efficacy of oral pre-exposure prophylaxis (PrEP), vaginal microbicides, and treatment as prevention, but there has also been significant progress in the development of rectal microbicides. The purpose of this review is to summarize the status of rectal microbicide research and to identify opportunities, challenges, and future directions in this important field of HIV prevention. Recent phase 1 rectal microbicide studies have characterized the safety, acceptability, compartmental pharmacokinetics, and pharmacodynamics of both UC781 and tenofovir gels. The tenofovir gel formulation used in vaginal studies was not well tolerated in the rectum and newer rectal-specific formulations have been developed and evaluated in phase 1 studies. Complex phase 1 studies have provided important data on candidate rectal microbicides."

According to the news editors, the research concluded: "Tenofovir gel is poised to move into phase 2 evaluation and it is possible that a phase 2B/3 effectiveness study could be initiated in the next 2-3 years."

For more information on this research see: Rectal microbicide development. Current Opinion In Hiv and Aids, 2012;7(6):526-33. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion In Hiv and Aids - journals.lww.com/co-hivandaids/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting I. McGowan, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States (see also Immune System Diseases and Conditions).

Keywords for this news article include: Anti Infectives, Therapy, HIV/AIDS, Pittsburgh, RNA Viruses, Pennsylvania, Retroviridae, United States, HIV Infections, Vertebrate Viruses, Risk and Prevention, Primate Lentiviruses, North and Central America, Viral Sexually Transmitted Diseases, Immune System Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC



 


Copyright © 2013 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS.



Information in this article was accurate in October 7, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.